Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igal Gery

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Frontiers in Immunology|December 16, 2014
The definition of lymphocyte activating factor: giving a helping hand to serendipityIgal Gery
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|March 8, 2017
Robert Burton Nussenblatt, MD, MPH (1948-2016), Physician-Scientist, Leading Ophthalmologist and Exemplary TeacherIgal Gery
Current Eye Research|April 18, 2009
Constitutive pro-apoptotic molecules are differentially expressed in the fetal and adult mouse eyeVanessa Montalvo, Igal Gery
Critical Reviews in Immunology|March 21, 2012
The unique features of Th9 cells and their productsCuiyan Tan, Igal Gery
International Reviews of Immunology|November 12, 2002
Central tolerance mechanisms in control of susceptibility to autoimmune uveitic diseaseIgal Gery, Charles E Egwuagu
Journal of Ophthalmic Inflammation and Infection|April 9, 2011
Remembering Professor David BenEzra, M.D., Ph.D., 1942-2008Igal Gery, Jorge L Alio
Frontiers in Immunology|October 26, 2018
Tolerance Induction in Relation to the EyeIgal Gery, Rachel R Caspi
Ophthalmic Research|April 19, 2008
Microbial products trigger autoimmune ocular inflammationChiaki Fujimoto, Guangpu Shi, Igal Gery
Investigative Ophthalmology & Visual Science|March 24, 2017
Chronic, Systemic Interleukin-18 Does Not Promote Macular Degeneration or Choroidal NeovascularizationScott W Canna, Guangpu Shi, Igal Gery, et al.
Ocular Immunology and Inflammation|April 5, 2005
The immunomodulator vasoactive intestinal peptide (VIP) does not affect experimental autoimmune uveitis (EAU) in B10.RIII miceJun Chen, Barbara Vistica, Barbara Wiggert, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Frontiers in Immunology|December 16, 2014
The definition of lymphocyte activating factor: giving a helping hand to serendipityIgal Gery
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|March 8, 2017
Robert Burton Nussenblatt, MD, MPH (1948-2016), Physician-Scientist, Leading Ophthalmologist and Exemplary TeacherIgal Gery
Current Eye Research|April 18, 2009
Constitutive pro-apoptotic molecules are differentially expressed in the fetal and adult mouse eyeVanessa Montalvo, Igal Gery
Critical Reviews in Immunology|March 21, 2012
The unique features of Th9 cells and their productsCuiyan Tan, Igal Gery
International Reviews of Immunology|November 12, 2002
Central tolerance mechanisms in control of susceptibility to autoimmune uveitic diseaseIgal Gery, Charles E Egwuagu
Journal of Ophthalmic Inflammation and Infection|April 9, 2011
Remembering Professor David BenEzra, M.D., Ph.D., 1942-2008Igal Gery, Jorge L Alio
Frontiers in Immunology|October 26, 2018
Tolerance Induction in Relation to the EyeIgal Gery, Rachel R Caspi
Ophthalmic Research|April 19, 2008
Microbial products trigger autoimmune ocular inflammationChiaki Fujimoto, Guangpu Shi, Igal Gery
Investigative Ophthalmology & Visual Science|March 24, 2017
Chronic, Systemic Interleukin-18 Does Not Promote Macular Degeneration or Choroidal NeovascularizationScott W Canna, Guangpu Shi, Igal Gery, et al.
Ocular Immunology and Inflammation|April 5, 2005
The immunomodulator vasoactive intestinal peptide (VIP) does not affect experimental autoimmune uveitis (EAU) in B10.RIII miceJun Chen, Barbara Vistica, Barbara Wiggert, et al.
Pageof 6